| Unique ID issued by UMIN | UMIN000043925 |
|---|---|
| Receipt number | R000042200 |
| Scientific Title | Safety Assessment of Ultra-low-flow and Low-flow Sevoflurane Anesthesia Using Carbon Dioxide Absorbent YABASHI LIME-f |
| Date of disclosure of the study information | 2021/04/14 |
| Last modified on | 2025/06/03 13:39:29 |
Safety Assessment of Ultra-low-flow and Low-flow Sevoflurane Anesthesia Using Carbon Dioxide Absorbent YABASHI LIME-f
SAULSAY
Safety Assessment of Ultra-low-flow and Low-flow Sevoflurane Anesthesia Using Carbon Dioxide Absorbent YABASHI LIME-f
SAULSAY
| Japan |
Colon cancer, Benign colorectal disease
| Surgery in general | Gastrointestinal surgery |
Malignancy
NO
In this study, we use Yabashilime-f and perform respiratory control under sevoflurane anesthesia with a fresh gas flow rate of 0.5 L / min (very low flow rate), 1 L / min (low flow rate), or 2 L / min of normal flow rate. In colorectal disease surgery, we will evaluate the concentration of Compound A in the anesthesia circuit over time and the presence or absence of postoperative acute kidney injury onset in patients. This will examine whether sevoflurane very low flow anesthesia and low flow anesthesia surgery can be performed without causing renal dysfunction.
Safety
Measurement of Compound A concentration in anesthesia circuit over time
Whether the patient has postoperative acute kidney disease
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Dose comparison
NO
YES
Institution is not considered as adjustment factor.
NO
No need to know
3
Treatment
| Device,equipment |
fresh gas frow rate 0.5 L/h
fresh gas frow rate 1 L/h
fresh gas frow rate 2 L/h
| 20 | years-old | <= |
| Not applicable |
Male and Female
Scheduled colon cancer resection ( over 6 hours anesthesia )
Renal function is normal (eGFR 90 or more) and liver function is normal (total bilirubin is 1.5 times or less of the upper limit of the medical institution's standard value and AST and ALT are 2.5 times or less of the upper limit of the medical institution's standard value)
18
| 1st name | Kimitoshi |
| Middle name | |
| Last name | Nishiwaki |
Nagoya university graduate school of medicine
Department of anesthesiology
466-8550
65 tsurumai showa nagoya
052-744-2340
nishi@med.nagoya-u.ac.jp
| 1st name | Takahiro |
| Middle name | |
| Last name | Ando |
Nagoya university hospital
Department of surgery section
466-8550
65 tsurumai showa nagoya
052-744-2340
bakagarasu7@gmail.com
Nagoya university graduate school of medicine
Nagoya university graduate school of medicine
Other
Nagoya university graduate school of medicine
65 tsurumai showa nagoya
052-744-2973
ethics@med.nagoya-u.ac.jp
NO
| 2021 | Year | 04 | Month | 14 | Day |
https://center6.umin.ac.jp/cgi-bin/ctr/ctr_up_reg_f3.cgi
Partially published
https://center6.umin.ac.jp/cgi-bin/ctr/ctr_up_reg_f5.cgi
45
In a total of 18 patients, the median anesthesia times were 497.0, 549.0, and 696.5 minutes for the 2.0 L/min, 1.0 L/min, and 0.5 L/min FGF groups, respectively. Compound A was not observed at all gas sampling points and was significantly lower than the threshold mean of 20 ppm. With regard to AKI onset, a total of two patients had creatinine content 1.5 times the reference value at POD 1 and were diagnosed as Stage 1 according to KDIGO guidelines.
| 2025 | Year | 04 | Month | 22 | Day |
Patients were recruited between November 2019 and June 2022. Inclusion criteria were as follows: patients with American Society of Anesthesiologists physical status 1 or 2, aged >20 years, and scheduled for elective colorectal resection. Patients with renal dysfunction (estimated glomerular filtration rate <90) or hepatic dysfunction (total bilirubin >1.5 times and <3.0 times the institutional upper limit, and/or aspartate aminotransferase or alanine aminotransferase >2.5 times the upper limit) were excluded. Additional exclusions included patients with preoperative risk factors for perioperative AKI, such as hypertension, diabetes mellitus, congestive heart failure, impaired cardiac function, use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, non-steroidal anti-inflammatory drugs (NSAIDs), antibacterial agents, or diuretics. Pregnant women were also excluded. Patients were randomly assigned to one of three groups based on FGF: 2.0, 1.0, or 0.5 L/min, using computer-generated randomization.
Enrollment: Assessed for eligibility (n=45)
Exclusion: Surgery canceled n=3, Exclusion criteria n=12
Randomization: Randomized (n=30)
Allocation: 0.5 L/min (n=9) 1.0 L/min (n=10) 2.0 L/min (n=11)
Withdraw(Not enough time for surgery): 0.5 L/min (n=3) 1.0 L/min (n=4) 2.0 L/min (n=5)
Complete study and analyses: 0.5 L/min (n=6) 1.0 L/min (n=6) 2.0 L/min (n=6)
Nothing of note
Measurement of Compound A concentration in anesthesia circuit over time
Whether the patient has postoperative acute kidney disease
Completed
| 2019 | Year | 08 | Month | 15 | Day |
| 2019 | Year | 08 | Month | 15 | Day |
| 2019 | Year | 08 | Month | 15 | Day |
| 2023 | Year | 03 | Month | 31 | Day |
| 2021 | Year | 04 | Month | 14 | Day |
| 2025 | Year | 06 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042200
| Research Plan | |
|---|---|
| Registered date | File name |
| 2025/04/22 | 臨床研究_計画書(麻酔科・安藤貴宏)0207.doc |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| 2025/04/22 | 症例データ仕様書.docx |
| Research case data | |
|---|---|
| Registered date | File name |
| 2025/04/22 | ANDO_T_Supplemental table_20241115.docx |
Value
https://center6.umin.ac.jp/ice/42200